Komori
Alfresa Holdings (2784) · FactFirst stated

FY2021-Q3 Revenue and Profit Declines in the Wholesale Business for Prescription Pharmaceuticals and Other Products

First written in FY2021-Q3. . Latest entry: FY2021-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Lower revenue and earnings in the wholesale business for prescription drugs and other pharmaceuticalsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2021-Q3First statedAnnual report

    「当セグメントの当第３四半期連結累計期間の業績は、薬価改定および新型コロナウイルス感染拡大等の影響による市場のマイナス成長ならびに価格競争の激化等により、売上高1兆7,464億77百万円(前年同期比4.0％減)、営業利益121億39百万円(同60.4％減)となりました。」

    医療用医薬品等卸売事業は、薬価改定、新型コロナウイルス感染拡大、市場のマイナス成長、価格競争激化等により減収減益となった。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Alfresa Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.